Dementia

Cubresa Installs First BrainPET Insert System at Lawson Health Research Institute

Retrieved on: 
Tuesday, May 30, 2023
Science, Other Science, Radiology, Oncology, Health, Medical Devices, Hospitals, Health Technology, Partnership, Ageing, PET, Lawson Health Research Institute, Brain, Research, DSM-IV codes, Google Images, Dementia, Lawson, Diagnosis, Medical imaging

Cubresa has installed the first BrainPET Insert System at St. Joseph’s Health Care London, in partnership with the hospital’s research institute – Lawson Health Research Institute.

Key Points: 
  • Cubresa has installed the first BrainPET Insert System at St. Joseph’s Health Care London, in partnership with the hospital’s research institute – Lawson Health Research Institute.
  • The Cubresa BrainPET is a removeable, high-performing PET scanner, specifically designed for PET/MRI brain imaging.
  • “We are very excited to receive the world’s first Cubresa BrainPET.
  • By operating inside of our existing 3T MRI, this head-only PET system will enhance the possibilities of brain imaging with superior image resolution,” said Dr. Jonathan Thiessen, Imaging Scientist at Lawson Health Research Institute.

Equify Health Receives $1 Million Grant to Launch Transformative Education Workshop to Accelerate Health Care Equity

Retrieved on: 
Wednesday, May 31, 2023
Insurance, Medicine, The New England Journal of Medicine, Senior, Emory University School of Medicine, Social impact, Health, Health equity, Cancer, Woman, Chest pain, American Academy, Research, Black, African Americans, Mandarin Oriental Hotel Group, Dementia, Patient, Physician, Risk, Nursing, Mortality, American Cancer Society, Breast cancer, Pharmaceutical industry, Genentech

MENLO PARK, Calif., May 31, 2023 /PRNewswire-PRWeb/ -- Equify Health, an innovation firm working to transform patient-provider experiences, was awarded a $1 million grant by leading biotechnology company Genentech. The grant will support the deployment of a multidisciplinary education program to train medical providers to shed unconscious biases in clinical practice. The ultimate goal behind the grant is to raise the quality of care for minority populations.

Key Points: 
  • "Negative barriers impacting minority patients are real," says Sylvie Leotin, the founder and CEO of Equify Health.
  • The new grant will allow Equify Health to expand its education workshop to doctors and nurses at academic hospitals and health care organizations across the United States.
  • With this second grant, Equify Health will expand its pilot workshop to additional institutions beyond Emory and enroll doctors across multiple specialties beyond cancer.
  • We believe this transformative education workshop will empower and engage medical providers to connect with marginalized patients in a more empathetic and inclusive way.

U.S. News & World Report Names Market Street Memory Care Residence Viera a Best Memory Care Community for 2 Consecutive Years

Retrieved on: 
Tuesday, May 30, 2023
Food, Research, Alzheimer's disease, Dementia, Senior living, Environment, Safety, News, Nursing, Management, U.S. News & World Report, U.S

VERO BEACH, Fla., May 30, 2023 /PRNewswire/ -- Market Street Memory Care Residence Viera celebrates the honor of being named a 2023-24 Best Memory Care Community by U.S. News & World Report.

Key Points: 
  • VERO BEACH, Fla., May 30, 2023 /PRNewswire/ -- Market Street Memory Care Residence Viera celebrates the honor of being named a 2023-24 Best Memory Care Community by U.S. News & World Report.
  • Market Street Viera is a 64-unit state-of-the-art memory care community in Melbourne, Florida, owned and operated by Watercrest Senior Living Group .
  • This is the second consecutive year Market Street Viera was prestigiously recognized by U.S. News & World Report, earning "Best" status by achieving the highest possible rating for Memory Care.
  • Market Street Memory Care Residence Viera offers world class care, multi-sensory programming, diverse culinary experiences, and unparalleled associate training honoring seniors with Alzheimer's and dementia.

ComForCare Establishes Exclusive Partnership with Connected Home Living to Launch Connected Care, Providing 24/7 Monitoring

Retrieved on: 
Tuesday, May 30, 2023
Blood pressure, Hive Connected Home, Partnership, Weakness, Falls, Dementia, Vital signs, Patient, Social isolation, Health, Caregiver, Nursing, Residential care, Tourism

TROY, Mich., May 30, 2023 /PRNewswire/ -- ComForCare, a franchised provider of in-home caregiving services, forges an exclusive partnership with Connected Home Living, the leader in remote patient care, to introduce Connected Care for clients. The new technology will be integrated into ComForCare/At Your Side's in-home care protocol to monitor vital signs, alerts, medications, mental and physical state of older adults cared for, on a daily basis, ensuring continuity of care and rapid intervention for best possible outcomes.

Key Points: 
  • TROY, Mich., May 30, 2023 /PRNewswire/ -- ComForCare , a franchised provider of in-home caregiving services, forges an exclusive partnership with Connected Home Living , the leader in remote patient care, to introduce Connected Care for clients.
  • Connected Care enhances care with:
    Fall Detection: the fall detection technology responds within minutes without the need for cameras or wearables.
  • Wellness Monitoring: non-intrusive sensors gather real-time activity and daily living patterns to establish a baseline for individuals.
  • Connected Care will be rolling out across ComForCare and At Your Side Home Care franchise locations over the next several months.

QuantalX Receives FDA Breakthrough Designation for Diagnosis of Normal Pressure Hydrocephalus and Prediction of Treatment Response

Retrieved on: 
Tuesday, May 30, 2023
CT, Vascular dementia, Prevalence, Shunt (electrical), DSM-IV codes, Stroke, Quality of life, Alzheimer's disease, Delphi, Cerebrospinal fluid, Dementia, KFAR, MRI, Science, Medtronic, Walking, VPS, Parkinson's disease, Patient, Risk, Physician, Diagnosis, Entrepreneurship, CSF, FDA, Health, NPH, Pharmaceutical industry, Medical imaging, Neuromodulation

KFAR SABA, Israel, May 30, 2023 /PRNewswire/ -- QuantalX, the developer of Delphi-MD, a novel point-of-care neurodiagnostic device, has announced that they have received the prestigious FDA breakthrough designation medical device status for another clinical application, Normal Pressure Hydrocephalus (NPH). The FDA recognized the innovative value of the device in diagnosing NPH patients and predicting the response to the recommended treatment for NPH, ventriculoperitoneal shunting (VPS) surgery.

Key Points: 
  • The FDA grants the Delphi-MD device breakthrough designation technology status for the diagnosis of Normal Pressure Hydrocephalus (NPH) patients and prediction of response to highly effective, ventriculoperitoneal shunting surgery (VPS) treatment.
  • KFAR SABA, Israel, May 30, 2023 /PRNewswire/ -- QuantalX, the developer of Delphi-MD, a novel point-of-care neurodiagnostic device, has announced that they have received the prestigious FDA breakthrough designation medical device status for another clinical application, Normal Pressure Hydrocephalus (NPH).
  • The FDA recognized the innovative value of the device in diagnosing NPH patients and predicting the response to the recommended treatment for NPH, ventriculoperitoneal shunting (VPS) surgery.
  • This marks the second time that the Delphi-MD device has been granted a breakthrough designated medical device by the FDA.

A little-understood sleep disorder affects millions and has clear links to dementia – 4 questions answered

Retrieved on: 
Saturday, May 27, 2023
Blood pressure, Smell, Pure autonomic failure, Association, Conversation, Melatonin, Tremor, RBD, Rapid eye movement sleep behavior disorder, Respiratory rate, Sleep, Deficit spending, Narcolepsy, Constipation, Quality of life, Multiple system atrophy, Brain, Research, Disorder, DSM-IV codes, Injury, Dementia, Clonazepam, Parkinsonism, Dream, Patient, Sleep disorder, Risk, Lewy body, Diagnosis, Erectile dysfunction, Obstructive sleep apnea, Color, Synucleinopathy, Disease, REM, Pharmaceutical industry

The disorder, known as REM sleep behavior disorder, or RBD in the medical field, affects around 1% of the general population worldwide and about 2% of adults over 65.

Key Points: 
  • The disorder, known as REM sleep behavior disorder, or RBD in the medical field, affects around 1% of the general population worldwide and about 2% of adults over 65.
  • The Conversation talked with Anelyssa D'Abreu, a neurologist who specializes in geriatric neurology, to explain what researchers know about the condition’s links to dementia.

1. What is REM sleep behavior disorder?

    • REM sleep only comprises 20% to 25% of total sleep, but its proportion increases throughout the night.
    • But someone with REM sleep behavior disorder will act out their dreams.
    • Appropriate testing, including a sleep study, are needed to determine if a patient has REM sleep behavior disorder, as opposed to another disorder, such as obstructive sleep apnea.
    • REM sleep behavior disorder can occur at any age, but symptoms usually start with people in their 40s and 50s.

2. What causes REM sleep behavior disorder?

    • In some cases of REM sleep behavior disorder, a clear cause cannot be identified.
    • In both situations, REM sleep behavior disorder may be associated with synucleinopathies, a group of neurodegenerative disorders in which aggregates of the protein α-synuclein accumulate in brain cells.
    • REM sleep behavior disorder may precede these diseases or occur at any time during the disease process.

3. What are the links between the sleep disorder and dementia?

    • REM sleep behavior disorder may be the first symptom of Parkinson’s disease or dementia with Lewy bodies.
    • After 12 years, 73.5% of those with REM sleep behavior disorder had developed a related neurodegenerative disorder.
    • REM sleep behavior disorder may also be observed in other neurodegenerative disorders such as Alzheimer’s disease and Huntington’s disease, but at much lower rates.

4. Does an early diagnosis help?

    • RBD, in that scenario, is an early sign of those disorders.
    • At this time, there are no approved therapies to prevent the onset of these neurodegenerative diseases in those with REM sleep behavior disorder.
    • We also recommend measures to avoid injury, such as removing breakable objects from the room, protecting windows and padding floors.

KAIST and Checkmate Capital Complete Investment in Bredis Healthcare

Retrieved on: 
Thursday, May 25, 2023
Pacific Ocean, Commercialization, Partnership, KAIST, Pusan National University, Prognosis, Research, Biomarker, ELISA, Dementia, Tomato bredie, Blood, Diagnosis, Ecosystem, Pharmaceutical industry, Medical imaging, Checkmate

SEOUL, Korea and PASADENA, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- KAIST Venture Investment Holdings (“KAIST” or “KAIST Ventures”), the venture investment fund of Korea Advanced Institute of Science and Technology, and an affiliate of Checkmate Capital Group, LLC (“Checkmate”), a cross-Pacific strategic advisory group and investment office, are pleased to announce the completion of their investment into Bredis Healthcare (“Bredis”). Bredis is a leading neurodegenerative diagnostics company that has pioneered its patent-protected, digital ELISA technology that is 10,000 times more sensitive than existing blood test technology.

Key Points: 
  • Investment Accelerates Bredis’ Capacity Expansion, Integrated Platform Development and Commercialization in Korea
    SEOUL, Korea and PASADENA, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- KAIST Venture Investment Holdings (“KAIST” or “KAIST Ventures”), the venture investment fund of Korea Advanced Institute of Science and Technology, and an affiliate of Checkmate Capital Group, LLC (“Checkmate”), a cross-Pacific strategic advisory group and investment office, are pleased to announce the completion of their investment into Bredis Healthcare (“Bredis”).
  • KAIST led the redeemable convertible preferred stock investment and Checkmate was the sole non-Korean investor.
  • As a startup team from KAIST, we believe Bredis will become a promising biomarker-based diagnostics enterprise that grows rapidly through the KAIST startup ecosystem,” commented Henry Chung, CEO of KAIST Ventures.
  • “We are delighted that Bredis is Checkmate’s first direct investment in Korea, sourced through our new international office based in Seoul, and our first collaborative investment with our trusted partner, KAIST,” stated Jay Ryu, Managing Director of Checkmate.

Mithra - Letter to Shareholders and Corporate Update

Retrieved on: 
Thursday, May 25, 2023
Highbridge, Gedeon Richter, Letter, Mayo Clinic, Drawing, Endometrium, Therapy, Arthralgia, File, Marketing, Birth, Silence Therapeutics, NDA, BL 2.75-inch mountain gun, Ageing, Woman, Quality of life, Hospira, Research, Negotiation, Attention, Brain, DRSP, Hot, GSI, MITRA, Incidence, Communication, EUR, Dementia, CDMO, System, Patient, CEST, Estrogen, Brussels Stock Exchange, Menopause, Liver, Growth, Mortality, MAA, FDA, Zealand Pharma, Management, Risk management, Pharmaceutical industry, Medical device, Security (finance), Mithra, Estetrol, White box

Donesta® filing rescheduled for H2 2023 - still expecting U.S. approval in H1 2024

Key Points: 
  • Donesta® filing rescheduled for H2 2023 - still expecting U.S. approval in H1 2024
    Liege, Belgium, 25 May 2023 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, (the "Company" or "Mithra"), today published a Corporate Update and Letter to Shareholders from recently appointed Chief Executive Officer, Dr. David Horn Solomon.
  • I accepted the role because my analysis revealed strong fundamentals and tremendous potential to create significant value for Mithra shareholders.
  • Collectively, the Mithra leadership understands that our ability to create value for our shareholders is a primary directive that goes hand in hand with developing medicines for women.
  • I look forward to continuing with increased transparency and regular communications to providing updates on our progress to you, our shareholders.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Lawsuit Against Acadia Pharmaceuticals, Inc. (ACAD) and Encourages Long-Term ACAD Investors to Contact the Firm

Retrieved on: 
Wednesday, May 24, 2023
Symantec Endpoint Protection, ACAD, New Drug Application, Dementia, Shanda, Acquisition, Patient, Psychiatry, CRL, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pimavanserin, News, Food, Cryptocurrency, Pharmaceutical industry

The company’s most valuable drug from a commercial perspective is pimavanserin, which Acadia touts as a treatment for dementia-related psychosis (“DRP”).

Key Points: 
  • The company’s most valuable drug from a commercial perspective is pimavanserin, which Acadia touts as a treatment for dementia-related psychosis (“DRP”).
  • Current Acadia stockholders who purchased or acquired shares of the company’s common stock prior to September 9, 2019 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.
  • Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis.
  • For additional information about Kaskela Law LLC please visit www.kaskelalaw.com .

Therapeutic Solutions International Launches Subsidiary Company to Commercialize Clinical Data and IND for Treatment of Chronic Traumatic Encephalopathy (CTE) with JadiCell Universal Adult Stem Cells

Retrieved on: 
Thursday, May 25, 2023
Research, FDA, Neurology, Clinical Trials, Stem Cells, Biotechnology, Other Health, Health, Science, Chronic traumatic encephalopathy, Depression, Specialization, Aggression, Football, TSOI, Dementia, Patient, Amnesia, IND, Safety, Pharmaceutical industry

Therapeutic Solutions International (TSOI) announced the creation of CTE Biologics, Inc. as a subsidiary company dedicated to commercializing the JadiCell adult stem cell platform for treatment of chronic traumatic encephalopathy.

Key Points: 
  • Therapeutic Solutions International (TSOI) announced the creation of CTE Biologics, Inc. as a subsidiary company dedicated to commercializing the JadiCell adult stem cell platform for treatment of chronic traumatic encephalopathy.
  • Therapeutic Solutions International licensed the JadiCell for this indication in 20191, was granted IND number 27377 in April 20212, and is currently addressing questions from the FDA before initiations of formal clinical trials.
  • The Company has provided JadiCells under the Right to Try Law for multiple patients suffering from Chronic Traumatic Encephalopathy3.
  • “Creation of CTE Biologics allows for specialization and focus while leveraging existing resources within Therapeutic Solutions International.”